AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 09 2024
0mins
Source: NASDAQ.COM
- AnaptysBio Quarterly Report: AnaptysBio, Inc. reported a quarterly loss of $1.64 per share, slightly below the Zacks Consensus Estimate, with adjusted figures for non-recurring items.
- Financial Performance: The company's earnings surprise was -6.49%, and it exceeded consensus EPS estimates three times in the last four quarters.
- Revenue Growth: AnaptysBio posted revenues of $7.18 million for the quarter, surpassing estimates by 57.78% and topping consensus revenue estimates two times in the last four quarters.
- Stock Movement: AnaptysBio shares have increased by about 20.2% since the beginning of the year, outperforming the S&P 500.
- Future Outlook: The company's future stock performance will depend on management's commentary and earnings outlook, with current estimates showing a Zacks Rank #3 (Hold) status.
Analyst Views on ANAB
Wall Street analysts forecast ANAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANAB is 71.33 USD with a low forecast of 50.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 47.330
Low
50.00
Averages
71.33
High
140.00
Current: 47.330
Low
50.00
Averages
71.33
High
140.00
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
